Linked Life Data

11826686

Source:http://linkedlifedata.com/resource/pubmed/id/11826686

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2002-2-5
pubmed:abstractText
Leukotrienes are potent pro-inflammatory mediators that have been shown to play a prominent role in the pathophysiology of asthma and associated allergic disorders including allergic rhinitis (AR) and atopic dermatitis (AD). In the treatment of these disorders, topical corticosteroids (TCS) are currently the most important anti-inflammatory agents, however, long-term application of TCS is associated with side-effects. Moreover, corticosteroids appeared not to inhibit the release of leukotrienes in humans in vivo. Therefore, leukotriene receptor antagonists (LTRAs) have been introduced into clinical practice and these specific oral drugs are currently registered as additive therapy in mild to moderate persistent asthma not controlled by inhaled corticosteroids. As for other allergic disorders, including AR, until recently only a few placebo-controlled studies with LTRAs have been performed. These (preliminary) data provide a basis for optimism, but clearly more long-term studies are needed to evaluate their clinical effectiveness, especially as add-on therapy.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0300-0729
pubmed:author
pubmed:issnType
Print
pubmed:volume
39
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
187-90
pubmed:dateRevised
2005-11-16
pubmed:meshHeading
pubmed:year
2001
pubmed:articleTitle
Leukotriene receptor antagonists: clinical potential in allergic rhinitis.
pubmed:affiliation
Department of Pulmonary Diseases, Erasmus University Medical Center Rotterdam, The Netherlands. z.diamant@gems.demon.nl
pubmed:publicationType
Journal Article, Review